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Abstract
Background: Overexpression of sphingosine kinase-1 (SPHK1) has been demonstrated to be associated with the
development and progression in various types of human cancers. The current study was to characterize the
expression of SPHK1 in salivary gland carcinomas (SGC) and to investigate the association between SPHK1
expression and progression of SGC.
Methods: The expression of SPHK1 was examined in 2 normal salivary gland tissues, 8 SGC tissues of various
clinical stages, and 5 pairs of primary SGC and adjacent salivary gland tissues from the same patient, using real-
time PCR and western blot analysis. Furthermore, the SPHK1 protein expression was analyzed in 159
clinicopathologically characterized SGC cases by immunohistochemistry. Statistical analyses were performed to
determine the prognostic and diagnostic associations.
Results: SPHK1 expression was found to be markedly upregulated in SGC tissues than that in the normal salivary
gland tissues and paired adjacent salivary gland tissues, at both mRNA and protein levels. Statistical analysis
revealed a significant correlation of SPHK1 expression with the clinical stage (P = 0.005), T classification (P = 0.017),
N classification (P = 0.009), M classification (P = 0.002), and pathological differentiation (P = 0.013). Patients with
higher SPHK1 expression had shorter overall survival time, whereas patients with lower SPHK1 expression had
better survival. Importantly, patients in the group without adjuvant therapy who exhibited high SPHK1 expression
had significantly lower overall survival rates compared with those with low SPHK1 expression. Moreover,
multivariate analysis suggested that SPHK1 expression might be an independent prognostic indicator for the
survival of SGC patients.
Conclusions: Our results suggest that SPHK1 expression is associated with SGC progression, and might represent
as a novel and valuable predictor for adjuvant therapy to SGC patients.
Background
Salivary gland carcinoma (SGC), a relatively rare neo-
plasm, accounts for 0.5% of all malignancies and approxi-
mately 3%-5% of all head and neck cancers worldwide
[1,2]. SGC is a special type of cancer owing to the wide
v a r i a t i o ni ni t sh i s t o l o g i c al and clinical features [3].
According to the WHO classification, SGC contains 24
different entities and consists of 4 main histopathological
types, namely, mucoepidermoid carcinoma (MEC), ade-
noid cystic carcinoma (ACC), acinic cell carcinoma
(AcCC), and salivary duct carcinoma (SDC). All other
types of SGC occur less frequently or rarely [1,3].
Although advances have been made in developing more
elegant techniques, new chemotherapeutic agents, and
radiotherapy, the prognosis of advanced SGC has not
been significantly improved. The overall survival at 5 and
10 years for SGC patients is 92% and 90%, respectively;
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any medium, provided the original work is properly cited.however, all the patients who had clinical stage III or IV
disease at diagnosis subsequently died [4]. Further, more
than 5% of patients suffered a recurrence at the primary
site and/or distant metastases, the latter of which are not
amenable to surgery or radiotherapy [5]. Therefore, it
will be of great clinical value to identify effective early
markers for the diagnosis and prognosis of the disease
and also novel therapeutic targets.
Mounting evidence suggests that dysregulation of lipo-
genesis/lipid metabolism is closely associated with the
initiation and progression of various types of cancer. For
instance, sphingosine-1-phosphate (S1P), a bioactive
lipid mediator, has been demonstrated to play critical
roles in fundamental biological processes, such as prolif-
eration, survival, migration, angiogenesis, and invasion
[6-11]. Consistent with this, the super-activation or
upregulation of SPHK1, which catalyzes the phosphory-
lation of sphingosine to S1P, is shown to be involved in
carcinogenesis. Overexpression of SPHK1 in NIH3T3
fibroblasts enhances cell proliferation and the ability of
anchorage-independent growth, as well as tumorigeni-
city, in NOD/SCID mice [12]. Further, silencing the
endogenous expression of SPHK1 in glioblastoma cells
and breast cancer cells leads to cell cycle arrest. Inhibi-
tion of SPHK1 using a dominant-negative form of
SPHK1 dramatically decreased tumor formation in nude
mice [13]. Blocking SPHK1 activity by using its inhibi-
tors, such as camptothecin or docetaxel, has been
demonstrated to suppress tumor growth and to reduce
tumor occurrence and metastases in nude mice [14,15].
Further, several studies have shown that ectopic expres-
sion of SPHK1 can protect cancer cells against apoptosis
in response to pro-apoptotic stimuli, such as treatment
with TNF-a, ionizing radiation, or anti-cancer drugs,
through multiple pathways [16,17]. It has been reported
that the upregulation of SPHK1 impairs the effectiveness
of chemotherapy in human PC-3 and LNCaP prostate
cancer cell lines [18,19]. Bonhoure et al. demonstrated
that ectopic expression of SPHK1 in HL-60 cells pro-
moted resistance to treatments with doxorubicin and
etoposide by reducing the production of ceramide [20].
Upregulation of SPHK1 protects LAMA84 erythromega-
karyocytic cells from imatinib by blocking the release of
cytochrome c and Smac/Diablo from mitochondria [21].
Indeed, the expression level of SPHK1 has been found
to be frequently upregulated in various tumor types,
including glioblastoma multiforme, intestinal adenoma,
acute erythroleukemia, prostate cancer, colon cancer,
and gastric cancer [22-26].
In the current study, we report, for the first time, the
characterization of SPHK1 expression in SGC of various
clinicopathological grades. We found that the expression
of SPHK1 was significantly correlated with the clinical
stage, TNM classification, and pathological differentiation
of SGC. Statistical analysis revealed that SPHK1 expres-
sion represents a potentially useful independent biomarker
for the prognosis of SGC patients and might serve as a
valuable predictor for adjuvant therapy to SGC patients.
Methods
Patients and tissue specimens
This study was conducted on a total of 159 paraffin-
embedded SGC samples, which were histopathologically
and clinically diagnosed at the Sun Yat-sen University
Cancer Center from 1995 to 2004. Fifty patients was
received adjuvant radiation therapy, which doses ranged
from 6 Gy as palliative single fraction to 60 Gy. Two
human normal salivary gland tissues were obtained from
patients with head and neck tumors during the surgical
procedure of neck dissection. For the use of these clinical
materials for research purposes, prior patient consent and
approval from the Institutional Research Ethics Commit-
tee were obtained. Clinical and clinicopathological classifi-
cation and staging were determined according to the
criteria proposed by WHO classification [3]. Clinical infor-
mation on the samples is summarized in Table 1. Five spe-
cimens of SGC tissues (Clinical stage II) and the matched
adjacent noncancerous salivary gland tissues were frozen
and stored in liquid nitrogen until further use.
RNA extraction and Real-time PCR
Total RNA from cells and primary tumor samples was
extracted using the Trizol reagent (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instruction. Real-
time PCR was performed according to standard methods
as described previously [26]. Sequences of the real-time
PCR primers were designed using the Primer Express
Software Version 2.0 and sequences are: SPHK1 forward
primer: 5′-CTTGCAGCTC TTCCGGAGTC-3′,S P H K 1
reverse primer 5′-GCTCAGTGAGCATCAGCGTG-3′,
SPHK1 probe 5′-(FAM)CCCTTTTGGCTGAGGCT-
GAAATC TCC(TAMRA)-3′. Expression data were nor-
malized to the geometric mean of housekeeping gene
GAPDH to control the variability in expression levels
(forward primer 5′-GACTCATGACCACAGTCCATGC-
3′, reverse primer 5′-AGAGGCAGGGATGATGTTCT
G-3′,a n dp r o b e5 ′-(FAM)CATCACTGC CACCCA-
GAAG ACTGTG(TAMRA)-3′) and calculated as 2
-[(Ct of
SPHK1)-( C to fGAPDH)],w h e r eC t represents the threshold
cycle for each transcript.
Western blotting
Western blotting was performed according to standard
methods as described previously [27], using rabbit anti-
SPHK1 (1:1000; Abgent, San Diego, CA). The mem-
branes were stripped and re-blotted with an anti-a-
tubulin antibody (Sigma, Saint Louis, MI) as a loading
control.
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Immunohistochemical analysis was performed to study
altered protein expression in two human normal salivary
gland tissues and 159 human salivary gland carcinomas
tissues. The procedures were carried out similarly to
previously described methods [26]. In brief, paraffin-
embedded specimens were cut into 4-μms e c t i o n sa n d
baked at 60°C for 2 hrs, followed by deparaffinization
with xylene and rehydrated. The sections were sub-
merged into EDTA antigenic retrieval buffer and micro-
waved for antigenic retrieval, after which they were
treated with 3% hydrogen peroxide in methanol to
quench endogenous peroxidase activity, followed by
incubation with 1% bovine serum albumin to block non-
specific binding. Sections were incubated with rabbit
anti-SPHK1 (Cat# AP7237c; Abgent, San Diego, CA)
overnight at 4°C. Normal goat serum was used as a
negative control. After washing, tissue sections were
treated with biotinylated anti-rabbit secondary antibody
(Zymed, San Francisco, CA), followed by further incuba-
tion with streptavidin-horseradish peroxidase complex
(Zymed, San Francisco, CA). Tissue sections were then
immersed in DAB (3.3′-diaminobenzidine) and counter-
stained with 10% Mayer’s hematoxylin, dehydrated and
mounted.
The degree of immunostaining was reviewed and
scored independently by 2 observers based on the pro-
portion of positively stained tumor cells and intensity of
staining. Tumor cell proportion was scored as follows: 0
(no positive tumor cells), 1 (<10% positive tumor cells),
2 (10-35% positive tumor cells), 3 (35-70% positive
tumor cells), and 4 (>70% positive tumor cells). Staining
intensity was graded according to the following criteria:
0 (no staining), 1 (weak staining = light yellow), 2 (mod-
erate staining = yellow brown), and 3 (strong staining =
brown). Staining index (SI) was calculated as the pro-
duct of staining intensity score and the proportion of
positive tumor cells. Using this method of assessment,
we evaluated SPHK1 expression in benign salivary gland
epithelia and malignant lesions by determining the SI,
with scores of 0, 1, 2, 3, 4, 6, 8, 9 or 12. The cutoff
value for high- and low-expression level was chosen on
the basis of a measure of heterogeneity with the log-
rank test statistical analysis with respect to overall survi-
val. An optimal cutoff value was identified: an SI score
of ≥6 was used to define tumors with high SPHK1
expression, an SI score of ≤4b u t>0w a su s e dt oi n d i -
cate low SPHK1 expression, and SI score of = 0 was
used to indicate no SPHK1 expression.
IHC staining for protein expression in tumor and nor-
mal tissues was quantitative analyzed with the AxioVi-
sion Rel.4.6 computerized image analysis system assisted
with the automatic measurement program (Carl Zeiss,
Oberkochen, Germany). Briefly, the stained sections
were evaluated at 200× magnification, and ten represen-
tative staining fields of each section were analyzed to
verify the Mean Optical Density (MOD), which repre-
sents the strength of staining signals as measured per
positive pixels. The MOD data were statistically
Table 1 Clinicopathological characteristics of SGC patient
samples
Number of cases (%)
Gender
Male 89 (56.0%)
Female 70 (44.0%)
Age (years)
≥47 81 (50.9%)
< 47 78 (49.1%)
Clinical Stage
I 16 (10.1%)
II 58 (36.5%)
III 39 (24.5%)
IV 46 (28.9%)
T classification
T1 17 (10.7%)
T2 72 (45.3%)
T3 37 (23.3%)
T4 33 (20.8%)
N classification
N0 118 (74.2%)
N1 21 (13.2%)
N2 20 (12.6%)
N3 0 (0.0%)
M classification
No 113 (71.1%)
Yes 46 (28.9%)
Pathologic Differentiation
Poor 101 (63.5%)
Moderate 4 (2.5%)
Well 54 (34.0%)
Histological Types
MEC 37 (23.3%)
ACC 23 (14.5%)
AcCC 18 (11.3%)
SDC 18 (11.3%)
Other histological types 63 (39.6%)
Vital status (at follow-up)
Alive 107 (67.3%)
Death (All Salivary Gland cancer-related) 52 (32.7%)
Adjuvant Therapy
Yes 50 (31.5%)
No 109 (68.6%)
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MOD difference between different groups of tissues, and
P < 0.05 was considered significant.
Statistical analysis
All statistical analyses were carried out using the SPSS
13.0 statistical software package. The chi-square test was
used to analyze the relationship between SPHK1 expres-
sion and clinicopathological characteristics. Bivariate
correlations between study variables were calculated by
Spearmans rank correlation coefficients. Survival curves
were plotted by the Kaplan-Meier method and com-
pared using the log-rank test. Survival data were evalu-
ated using univariate and multivariate Cox regression
analyses. P < 0.05 in all cases was considered statistically
significant.
Results
Expression of SPHK1 is upregulated in SGC
To investigate whether SPHK1 expression is upregulated
in clinical SGC tissues, real-time PCR analysis and wes-
tern blot analysis were performed in 2 normal salivary
gland tissues and 8 fresh-frozen SGC tissues. As shown
in Fig. 1A, real-time PCR results showed that all SGC
tissues exhibited significantly higher levels of SPHK1
mRNA compared with normal salivary gland tissues. In
parallel with the upregulation of mRNA, western blot
analysis revealed that SPHK1 protein was overexpressed
in all 8 SGC, whereas it was barely detectable in normal
salivary gland tissues (Fig. 1B).
Comparative analysis was conducted to examine the
expression of SPHK1 in 5 pairs of primary SGC tissue
and adjacent noncancerous tissue. Real-time PCR analy-
sis revealed that SPHK1 mRNA was overexpressed in
the 5 primary SGC samples compared with the paired
adjacent noncancerous salivary gland tissues, the over-
expression was as high as 12.5-fold in 1 of the 5 paired
primary SGC tissues (Fig. 2A). Meanwhile, the expres-
sion of the SPHK1 protein was also found to be upregu-
lated in all the 5 human primary SGC tissue samples as
compared to the expression in their matched adjacent
noncancerous tissues using western blot (Fig. 2B).
Importantly, protein quantification of western blotting
analysis (intensity) showed that all 5 tumors displayed a
more than 3-fold increase in SPHK1 protein compared
with the tissues adjacent to the tumors (Fig. 2C). The
abovementioned result was further confirmed by immu-
nohistochemistry (IHC) analyses (Fig. 2D). Taken
together, our results suggest that SPHK1 is upregulated
at both the mRNA and protein levels in SGC.
Overexpression of SPHK1 protein in archived SGC
samples
To further evaluate whether SPHK1 protein upregula-
tion is linked to the clinicalp r o g r e s s i o no fS G C ,I H C
analysis was performed to examine the SPHK1 protein
expression in 2 paraffin-embedded normal salivary gland
tissue samples and 159 paraffin-embedded, archived
SGC tissue samples, including 9 histological types of
SGC. i.e. mucoepidermoid carcinoma (MEC), adenoid
cystic carcinoma (ACC), acinar cell carcinoma(AcCC),
salivary duct carcinoma(SDC), basal cell carcinoma
(BCC), lymphoepithelial carcinoma(LEC), squamous cell
carcinoma(SCC), papillary adenocarcinoma(PAC) and
small cell undifferentiated carcinoma(SCUC). The
immunohistochemical results are summarized in Table
1 and 2. SPHK1 protein was detected in 154 of the 159
(96.9%) cases. As shown in Fig. 3A and 3B, the expres-
sion of SPHK1 was upregulated in all the examined his-
tological types of SGC compared with the normal
Figure 1 SPHK1 expression is upregulated in SGC tissues. (A and B) Expression analyses of SPHK1 mRNA and protein in 2 normal human
salivary gland tissues and 8 SGC tissues by real-time PCR (A) and western blotting (B). Data in A to B was performed three independent times
with similar results. *, P < 0.05.
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were present in areas containing the primary SGC cells,
whereas SPHK1 was undetectable or only marginally
detectable in the adjacent noncancerous tissues in all
tumor sections and in normal salivary gland tissues.
SPHK1 was mainly localized in the cytoplasm of primary
cancer cells, which is consistent with previous reports
on SPHK1 expression in other cancer types [22-26]. In
order to avoid possible bias caused by selecting fields
that have more cells or those that are heavily stained,
the representative staining fields of each tumor sample
were further analyzed to verify the mean optical density
(MOD). Quantitative analysis indicated that the average
MOD of SPHK1 staining in primary tumors of clinical
stages I-IV were statistically significantly higher than
those in normal salivary gland tissue (P < 0.001, Fig.
3C). Taken together, these observations suggested that
SPHK1 protein is overexpressed in archived SGC
samples.
Increased expression of SPHK1 is correlated with the
clinical features of SGC
The results of the immunohistochemical analyses of
SPHK1 levels were further statistically analyzed to deter-
mine the relationship with the clinical features of SGC.
As shown in Table 3, SPHK1 expression was significantly
correlated with the clinical stage (P = 0.005),
T classification (P = 0.017), N classification (P = 0.009), M
classification (P = 0.002) and pathological differentiation
Figure 2 Expression of SPHK1 is elevated in human primary SGC tissues compared with adjacent noncancerous tissues. (A) Expression
of SPHK1 mRNA in each of the primary SGC tissues (T) and SGC-adjacent noncancerous tissues (ANT) in the same patient, determined by real-
time PCR. (B and C) Expression (B) and Quantification (C) of SPHK1 protein in each of the primary SGC tissues (T) and SGC-adjacent
noncancerous tissues (ANT) in the same patient, determined by western blotting. (D) Expression of SPHK1 protein in each of the primary SGC
tissues (T) and SGC-adjacent noncancerous tissues (ANT) in the same patient, determined by immunohistochemistry (IHC). Data in A to D was
performed three independent times with similar results. *, P < 0.05.
Table 2 The expression of SPHK1 in Salivary Gland
Cancer
Expression of SPHK1
Negative 5 (3.1%)
Positive 154 (96.9%)
Low expression 69 (46.5%)
High expression 85 (53.5%)
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ciated with age, gender, or histological type. The above
results were further analyzed using Spearman correlation
analysis, which revealed that the Spearman correlation
coefficients between SPHK1 expression levels and clinical
stage, T classification, N classification, M classification,
and pathological differentiation were 0.277 (P <0 . 0 0 1 ) ,
0.239 (P = 0.020), 0.158 (P = 0.004), 0.234 (P = 0.003), and
0.245 (P = 0.020), respectively (Table 4). Taken together,
these results indicate that the overexpression of SPHK1 is
correlated with the clinical features of SGC.
SPHK1 expression is associated with the prognosis of
patients with SGC
Patient survival analysis were conducted and revealed
that SPHK1 protein expression in SGC was significantly
associated with the survival time of patients (P <0 . 0 0 1 ) ,
with a correlation coefficient of -0.363, clearly indicating
that the expression of SPHK1 was inversely correlated
with survival time (Table 5). Furthermore, Kaplan-Meier
analysis and the log-rank test were used to evaluate the
effects of clinicopathological characteristics, including
age, gender, histological type, clinical stage, T classifica-
tion, N classification, and M classification, in conjunc-
tion with SPHK1 protein expression, on patient survival.
As shown in Fig. 4A, the length of survival time was sig-
nificantly different between the patients with low and
high SPHK1 expression (P = 0.001), with the high
SPHK1 expression group having a shorter overall survi-
val time. The cumulative 5-year survival rate was 93.4%
(95% confidence interval, 0.854-0.914) in the low SPHK1
expression group, whereas it was only 46.3% (95% confi-
dence interval, 0.369-0.573) in the high SPHK1 expres-
sion group. Furthermore, univariate and multivariate
analyses were performed to determine whether the
SPHK1 expression level is an independent prognostic
factor of patient outcome. As shown in Table 4, clinical
stage, N classification and pathologic classification, as
well as SPHK1 expression, were identified as indepen-
dent prognostic factors, indicating that SPHK1 might be
a valuable marker for SGC patient diagnostic period.
Moreover, we evaluated the prognostic value of SPHK1
expression in selected patient subgroups. Although we
did not find any difference in the overall survival times of
patients between the low and high SPHK1 expression
groups in the early clinical subgroup (stages I-II, n = 74;
log-rank, P = 0.75; Fig. 4B, left panel), the patients in the
advanced disease group (stages III-IV) with tumors exhi-
biting high SPHK1 expression had significantly lower
overall survival rates compared with those with a low
level of SPHK1 expression (n = 85; log-rank, P =0 . 0 0 4 ;
Fig. 4B, right panel). Interestingly, statistical analysis
revealed a significant difference between the curves of
low and high SPHK1-expressing patients grouped by
Figure 3 SPHK1 protein is overexpressed in SGC histopathological sections as examined by immunohistochemistry. (A and B)
Representative images from immunohistochemical (IHC) analyses of normal human salivary gland tissues and 159 primary SGC specimens (A),a s
well as 9 histological types (B). (C) Statistical analyses of the average MOD of SPHK1 staining between normal salivary gland tissues (3 cases) and
SGC specimens of different clinical stage (16 cases per stage). * P < 0.05
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0.01; Fig. 4C, left panel), but no difference between the
curves of low and high SPHK1-expressing patients
grouped by well pathologic differentiation (n = 54; log-
rank, P = 0.858; Fig. 4C, right panel). Taken together, our
data suggest that SPHK1 might be a novel and potentially
useful independent biomarker for the prognosis of
patients with SGC.
SPHK1 expression might be a valuable predictor for
adjuvant therapy to SGC patients
Importantly, when the prognostic value of SPHK1
expression was evaluated in patient subgroups according
to treatment (with or without adjuvant therapy), we
found that the patients in the group without adjuvant
therapy and with tumors exhibiting high SPHK1 expres-
sion had significantly lower overall survival rates com-
pared with those with low SPHK1 expression (n = 109;
log-rank, P <0 . 0 0 1 ;F i g .5 A ) .H o w e v e r ,i nt h ea d j u v a n t
therapy group, the length of survival time did not differ
significantly between the patients with low and high
SPHK1 expression (n = 50; log-rank, P = 0.695; Fig. 5B).
Furthermore, statistical analysis showed that the cumu-
lative 5-year survival rate in the group without adjuvant
therapy was 79.9% (95% confidence interval, 0.712-
0.891) in the low SPHK1 expression group, whereas it
was only 45.1% (95% confidence interval, 0.336-0.566) in
the high SPHK1 expression group. Moreover, the prog-
nostic value of similar expression of SPHK1 was
Table 3 Correlation between SPHK1 expression and clinicopathologic characteristics of SGC
Characteristics SPHK1 Chi-square test P-value
Low or none No. cases (%) High No. cases (%)
Gender Male 45 (67.2) 44 (47.8) 0.150
Female 22 (32.8) 48 (52.2)
Age (years) ≥ 47 34 (50.7) 47 (51.1) 0.966
< 47 33 (49.3) 45 (48.9)
Clinical Stage I 10 (13.5) 6 (7.1) 0.005
II 35 (47.3) 23 (27.1)
III 16 (21.6) 23 (27.1)
IV 13 (17.6) 33 (38.8)
T classification T1 10 (13.5) 7 (8.2) 0.017
T2 40 (54.1) 32 (37.6)
T3 16 (21.6) 21 (24.7)
T4 8 (10.8) 25 (29.4)
N classification N0 60 (81.1) 58 (68.2) 0.009
N1 9 (12.2) 12 (14.1)
N2 5 (6.8) 15 (17.6)
N3 0 (0.0) 0 (0.0)
M classification No 61 (80.6) 52 (64.1) 0.002
Yes 13 (19.4) 33 (35.9)
Pathologic Differentiation Poor 57(35.8) 44(27.7) 0.013
Moderate 4(2.5) 0(0.0)
Well 24(15.1) 30(18.9)
Histological Types MEC 15(20.3) 22(25.9) 0.945
ACC 11(14.9) 12(14.1)
AcCC 9(12.2) 9(10.6)
SDC 9(12.2) 9(10.6)
Other histological types 30(40.5) 33(38.8)
Table 4 Spearman correlation analysis between SPHK1
and clinical pathologic factors
Variables SPHK1 expression level
Spearman Correlation P-Value
Clinical staging 0.277 <0.001
T classification 0.239 0.020
N classification 0.158 0.004
M classification 0.234 0.003
Pathologic Differentiation 0.245 0.020
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(with or without adjuvant therapy). As shown in Fig. 5C,
in the high SPHK1 expression group, the length of sur-
vival time did not differ significantly between the
patients with or without adjuvant therapy (n = 85; log-
r a n k ,P=0 . 8 0 8 ;F i g .5 C ) .M e a n w h i l e ,w ef o u n dt h a tt h e
patients with tumors exhibiting low SPHK1 expression
and in the group with adjuvant therapy had lower over-
all survival rates compared with those without adjuvant
therapy (n = 74; log-rank, P = 0.02; Fig. 5D), which sug-
gested that the adjuvant therapy is not suitable to the
patient with tumors exhibiting low SPHK1 expression.
Taken together, our results suggest that SPHK1 expres-
sion might be a novel and valuable predictor for adju-
vant therapy to SGC patients.
Discussion
The key finding of the present study is that the elevated
expression of SPHK1 protein is correlated with a poor
prognosis and reduced survival of SGC patients, suggest-
ing that SPHK1 is a potential independent prognostic
factor for SGC. We found that SPHK1 is upregulated in
clinical SGC tissues at both the mRNA and protein
levels compared with normal salivary gland tissues.
Furthermore, statistical analysis of the immunohisto-
chemical results revealed that the expression level of
SPHK1 protein is significantly correlated with SGC clin-
ical characteristics, including clinical stage, TNM
classification and pathological differentiation. Moreover,
those SGC patients who do not receive adjuvant therapy
and who exhibit high SPHK1 expression have a signifi-
cantly lower overall survival rate compared with those
with low SPHK1 expression, indicating that SPHK1
expression might represent a valuable predictor for adju-
vant therapy for SGC patients.
Owing to the rarity and histological diversity of SGC,
the clinical judgments regarding diagnosis and treat-
ment, as well as the prognosis, always present consider-
able difficulty [1,2,4,5]. Multiple molecular markers have
been shown to be associated with the progression and
development of SGC. Several groups have demonstrated
that HER2/neu is overexpressed at both the protein and
mRNA levels in SGCs, ACCs, and MECs [28-31].
Further studies have shown that the high HER2/neu
expressing patients with ACC have a significantly
shorter disease-free interval compared to those with low
HER2/neu expression [32]. Moreover, the expression of
HER-2/neu is correlated with local disease recurrence,
distant disease metastasis, and overall survival of differ-
ent histological types in SGC patients [33-36]. In addi-
tion, the expression of mutated tumor suppressor gene
p53 (in which mutations occur most frequently in exons
7 and 8) has been shown to be associated with the
relapse, M classification, and poor prognosis of SDC
patients [37]. H-ras mutations, found in various solid
tumor types, have also been demonstrated to occur
Table 5 Univariate and multivariate analyses of various prognostic parameters in patients with SGC Cox-regression
analysis
Univariate analysis Multivariate analysis
No. patients P Regression coefficient (SE) P Relative risk 95% confidence interval
Clinical stage
I 16 <0.001 0.214(0.639) 0.003 1.894 1.244-2.884
II 58
III 39
IV 46
N classification
N0 118 <0.001 0.203(0.764) <0.001 2.146 1.441-3.196
N1 21
N2 20
N3 0
Pathologic Differentiation
Poor 101 <0.001 0.168(0.358) 0.033 0.699 0.503-0.972
Moderate 4
Well 54
Expression of SPHK1
Low expression 74 0.001 0.324(0.657) 0.042 1.929 1.023-3.636
High expression 85
SPHK1 protein expression level in SGC significantly correlated with patient survival time (P < 0.001); the correlation coefficient was -0.363, indicating that higher
levels of SPHK1 expression correlated with shorter survival time.
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tumor grade of MECs [38,39]. Moreover, Lequerica-
Fernández and colleagues reported that VEGF is upre-
gulated in 62% of SGC tissues. Further, the expression
of VEGF is significantly correlated with lymph node
metastasis (P < 0.005), clinical stage (P <0 . 0 2 ) ,a n dd i s -
ease-specific survival (P < 0.01), suggesting that VEGF
might contribute to the progression and development of
SGC [40]. However, none of these studies established
whether these biomarkers could be used as treatment
(adjuvant therapy) predictors or indicators to SGC
patients. In the current study, we found that the cumu-
lative 5-year survival rate of patients with high SPHK1
expression but without adjuvant therapy was only 45.1%
(95% confidence interval, 0.336-0.566). However, it
increased to 79.9% (95% confidence interval, 0.712-
0.891) in the low SPHK1 expression group even without
adjuvant therapy. These results indicate that SPHK1
expression might be a valuable clinical predictor of adju-
vant therapy to SGC patients. Furthermore, statistical
analysis revealed no difference in the length of survival
time between the low and high SPHK1-expressing
patients receiving adjuvant therapy, indicating that
SPHK1 expression might also represent a valuable clini-
cal indicator of adjuvant therapy to SGC patients. Mean-
while, we found that the patients with tumors exhibiting
low SPHK1 expression and in the group with adjuvant
therapy had lower overall survival rates compared with
those without adjuvant therapy, which suggested that
the adjuvant therapy is not suitable to the patient with
tumors exhibiting low SPHK1 expression.
Recently, accumulating evidence has suggested that
SPHK1 functions as an onco-enzyme that is closely
involved in carcinogenesis [20,41,42]. Numerous studies
have demonstrated that upregulation of SPHK1 can pro-
mote cell proliferation and enhance the resistance to
apoptosis induced by different stimuli, and that this
upregulation is linked to the failure of clinical cancer
therapies, such as chemotherapy and radiotherapy
[14,15,18-21]. Consistent with these observations,
SPHK1 mRNA and protein levels have been found to be
significantly elevated in various tumor types [22-26],
Figure 4 Kaplan-Meier curves with univariate analyses (log-rank) for patients with low SPHK1 expression versus high SPHK1
expression tumors. (A) Patients with low SPHK1 expression (bold line) had a cumulative 5-year survival rate of 93.4% (95% confidence interval,
0.854-0.914), compared to the 46.3% for patients with high SPHK1 expression (dotted line; 95% confidence interval, 0.369-0.573). (B) Statistical
analysis of the difference between the tumors with high and low SPHK1 expression in the clinical stages I and II (left) and clinical stages III and
IV (right) patient subgroups. (C) Statistical analysis of the difference between tumors with high and low SPHK1 expression in the poor pathologic
differentiation (left) and well pathologic differentiation (right) patient subgroups. P values were calculated using the log-rank test.
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Page 9 of 12which prompted us to ask whether the expression of
SPHK1 is upregulated and clinically associated with the
progression of SGC. To address this question, we
examined the expression of SPHK1 under 3 different
circumstances, namely, in normal salivary gland and
fresh-frozen SGC tissues, in paired primary SGC tissue
and adjacent noncancerous tissue, and in a large cohort
of paraffin-embedded SGC tissues. Our data showed
that the upregulation of SPHK1 mRNA and protein is a
universal and frequent event in human SGC tissues, which
indicates that SPHK1 overexpression might be associated
with the development and progression of SGC. Impor-
tantly, 154 (96.9%) of 159 paraffin-embedded archived
SGC specimens, including 9 histological types, exhibited
positive staining for SPHK1 in the tumor cells, whereas
the adjacent noncancerous cells and normal salivary gland
tissue expressed little, if any, SPHK1. Furthermore, statisti-
cal analysis of the relationship between SPHK1 staining
and the clinicopathological characteristics of the patients
revealed a significant correlation between SPHK1 expres-
sion and the clinical stage, TNM classification, and patho-
logical differentiation of SGC, further supporting the
notion that SPHK1 might play a role in the progression of
SGC. It is particularly noteworthy that high SPHK1
expression is associated with a shorter survival time. The
cumulative 5-year survival rate was 93.4% (95% confidence
interval, 0.854-0.914) in the low SPHK1 expression group,
whereas it was only 46.3% (95% confidence interval, 0.369-
0.573) in the high SPHK1 expression group, suggesting
the possibility that SPHK1 can be used as a predictor for
patient prognosis and survival.
Conclusions
We have demonstrated that the elevated expression of
SPHK1 is significantly correlated with the development
and progression of SGC. The expression of SPHK1
might represent a novel and potentially independent
biomarker for the prognosis of patients with SGC, as
Figure 5 Kaplan-Meier analysis showing the overall survival of SGC patients categorized according to whether adjuvant therapy was
provided or not. (A and B) Statistical significance of the difference between the curves of the patients showing high and low SPHK1
expression was compared in the non-adjuvant therapy (A) and adjuvant therapy (B) patient subgroups. (C and D) Statistical significance of the
difference between the curves of the patients showing same SPHK1 expression was compared in the non-adjuvant therapy (C) and adjuvant
therapy (D) patient subgroups. P values were calculated using the log-rank test.
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Page 10 of 12well as a novel and valuable predictor for adjuvant ther-
apy to SGC patients. However, in addition to biopsies or
surgical tissues, it will be of great interest to investigate
whether such an important marker is also detectable in
other types of patient samples, such as salivary juice,
blood, and oral mucosa. Analysis of such samples would
contribute significantly to the detection of SGC at the
earliest possible stage, as well as indicating the most
appropriate and effective treatment for SGC patients,
thereby improving the their chances of recovery and
survival.
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